Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: A randomised, double-blind, phase 3, non-inferiority study

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 3, 2015, Pages 191-197

  Inagaki, Nobuya ^a   Onouchi, Hitoshi ^b   Maezawa, Hideaki ^b   Kuroda, Shingo ^b   Kaku, Kohei ^c  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; HEMOGLOBIN A1C; PLACEBO; TRELAGLIPTIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; URACIL;

ADULT; ALLERGIC RHINITIS; ALLERGY; ARTHRALGIA; ARTICLE; BACKACHE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EOSINOPHILIA; FEMALE; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INFLUENZA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; THORAX PAIN; TREATMENT OUTCOME; VERTIGO; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PIPERIDINES; URACIL;

EID: 84924062138     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70251-7     Document Type: Article

References (24)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
3. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
4. Briesacher BA, Andrade SE, Fouayzi H, Chan KA Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008, 28:437-443.
5. Cramer JA A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224.
6. Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One 2012, 7:e32412.
7. Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013, 15:55-61.
8. Kruk ME, Schwalbe N The relation between intermittent dosing and adherence: preliminary insights. Clin Ther 2006, 28:1989-1995.
9. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 2011, 13:144-149.
10. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012, 18:527-539.
11. Dezii CM, Kawabata H, Tran M Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002, 95:68-71.
12. Donnan PT, MacDonald TM, Morris AD Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002, 19:279-284.
13. Matsuno K, Horayama M, Araki T, et al. Evaluation for sustained DPP-4 inhibitory effect of SYR-472, a novel DPP-4 inhibitor, in Japanese healthy subjects [in Japanese]. J Japan Diabetes Soc 2012, 55(suppl 1):S-117. (abstr I-P-38).
14. Inagaki N, Onouchi H, Sano H, Funao N, Kuroda S, Kaku K SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014, 2:125-132.
15. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to national glycohemoglobin standardization program values. J Diab Invest 2012, 3:39-40. for the Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society.
16. Yabe D, Watanabe K, Sugawara K, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig 2012, 3:70-79.
17. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 2011, 27:1781-1792.
18. Draft guidance for industry. Diabetes mellitus: developing drug and therapeutic biologics for treatment and prevention 2008, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville.
19. García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013, 4:175-194.
20. Kardas P The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005, 7:722-728.
21. Paes AH, Bakker A, Soe-Agnie CJ Impact of dosage frequency on patient compliance. Diabetes Care 1997, 20:1512-1517.
22. Recker RR, Gallagher R, MacCosbe PE Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005, 80:856-861.
23. Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Che 2014, 57:3205-3212.
24. Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013, 56:696-708.